Last update 01 Nov 2024

Oligoasthenozoospermia

Last update 01 Nov 2024

Basic Info

Synonyms

Oligoasthenozoospermia, Oligoasthenozoospermia (finding), 乏精子・精子無力症

+ [1]

Introduction-

Drugs associated with Oligoasthenozoospermia

STSP-0902

Target

NGF

Mechanism

NGF modulators

Active Org.

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Originator Org.

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Active Indication

Neurotrophic keratitis [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Linggui Yangyuan Paste

Target-

Mechanism-

Active Org.

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Originator Org.

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Active Indication

Asthenozoospermia [+1]

Inactive Indication-

Drug Highest PhaseEarly Phase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Oligoasthenozoospermia

CTR20242413 / RecruitingPhase 1

随机、双盲、安慰剂对照、单剂量递增评价STSP-0902注射液在健康受试者中的安全性、耐受性、药代动力学特征及免疫原性的Ia期临床研究

[Translation] A randomized, double-blind, placebo-controlled, single-ascending dose phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of STSP-0902 injection in healthy subjects

主要目的：评价STSP-0902注射液单次皮下给药在健康受试者中的安全性和耐受性。次要目的：评价STSP-0902注射液单次皮下给药在健康受试者中的药代动力学(PK)及免疫原性。探索性目的：评价STSP-0902注射液单次皮下给药时健康受试者精液相关检测指标的变化。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single subcutaneous administration of STSP-0902 injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetics (PK) and immunogenicity of a single subcutaneous administration of STSP-0902 injection in healthy subjects. Exploratory objective: To evaluate the changes in semen-related test indicators in healthy subjects after a single subcutaneous administration of STSP-0902 injection.

Start Date31 Jul 2024

Sponsor / Collaborator

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

NCT06088693 / CompletedNot Applicable

The Role of Electroacupuncture With Standard Therapy on Sperm Analysis and SOD Levels in Oligozoospermia.

The goal of this clinical trial is to compare in Oligozoospermia Patient. The main questions it aims to answer are: 1. Electroacupuncture therapy and standard therapy can affect oligozoospermia. 2. Electroacupuncture therapy and standard therapy can affect semen and spermatozoa plasma SOD levels.
Researchers will compare patient with standard therapy with patient with standard therapy with electroacupuncture.

Start Date11 Sep 2023

Sponsor / Collaborator

University of Indonesia

CTIS2023-508430-34-00 / Recruiting

A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility

Start Date13 Jul 2023

Sponsor / Collaborator

Ferring Pharmaceuticals A/S

100 Clinical Results associated with Oligoasthenozoospermia

100 Translational Medicine associated with Oligoasthenozoospermia

0 Patents (Medical) associated with Oligoasthenozoospermia

413

Literatures (Medical) associated with Oligoasthenozoospermia

31 Dec 2024·The Aging Male

Age related semen parameters and ICSI pregnancy outcomes of 8046 men in Turkey over a 9-year period

Article

Author: Cincik, Mehmet ; Valizade, Khayala ; Donmez Cakil, Yaprak ; Selam, Belgin ; Bayram, Hale

The effect of paternal age on fertility remains unclear. This retrospective study aims to examine the impact of male age on semen parameters and the reproductive outcomes of men admitted to an infertility center over a 9-year period. A total of 8046 patients were included in the study. Men were divided into four age groups. The groups were evaluated for semen parameters and reproductive outcome. The 21-30 year group presented lower sperm concentrations in comparison to those aged 31-40 and 41-50, yet shared a similar concentration to those over 50 years of age. Moreover, grades A and B decreased significantly in men aged over 50 years. The highest progressive motility and normozoospermia were observed in the age group 31-40 years while men over 50 years of age had the highest rates of asthenozoospermia and oligoasthenozoospermia. Furthermore, live birth results were reported in 5583 of the patients who underwent intracytoplasmic sperm injection (ICSI) and were found highest between 31-40 years of age. To our knowledge, this is the largest study in Turkey focusing on male age-related semen parameters and ICSI pregnancy outcomes. The study demonstrates that age is a significant factor for semen quality and live birth.

11 Sep 2024·Reviews on Recent Clinical Trials

Assessing Seminal Plasma Malondialdehyde Acid as a Diagnostic Tool for Male Infertility: A Case-Control Study

Article

Author: Padugupati, Suhasini ; Kumar, Naina ; Ghose, Seetesh ; Deepthi, KN

Aim:The aim of this study was to assess the role of seminal Malondialdehyde Acid (MDA) in the diagnosis of male infertilityBackground:Both male and female infertility is increasing all over the world.Objective:The purpose of this study was to assess the impact of seminal MDA levels on various semen parameters of healthy fertile men and men with infertility, and to know the efficacy of seminal MDA in the diagnosis of male infertilityMethods:This case-control study was carried out at the Department of Obstetrics and Gynaecology of a tertiary care center in rural Southern India over a period of two years. The study included 90 infertile men (≥21-50 years) having some pathology in semen reports as cases and 90 fertile men (having biological children) with normal semen reports as controls. Biochemical tests for MDA were performed using Human MDA Assay kits on 180 cryopreserved semen samples following the standard protocol. Results of seminal MDA levels were assessed among cases and controls and correlated with different semen parameters.Results:The mean±SD age for cases was 30.10 ± 4.75 years, and for controls, it was 29.79 ± 5.08 years. Of all the cases, 44 (48.9%) had asthenozoospermia, 22 (24.4%) had oligoasthenozoospermia, 14(15.6%) had oligozoospermia, and 10 (11.1%) had azoospermia. A statistically substantial variance was observed in mean values of MDA (1.03 ± 0.31 mmol/mL vs. 0.60 ± 0.14 mmol/mL; p =0.001) between fertile men and men with abnormal semen reports. A negative association was observed between semen MDA levels with sperm motility, concentration, and normal morphology in 180 participants. The sensitivity of MDA for male infertility prediction was 86.67% at 76.67% specificity, 78.79% positive predictive value, and 78.79% negative predictive value.Conclusion:MDA has been found to be a promising biomarker for predicting male infertility. However, large sample sizes and prospective cohort studies are required to further confirm its predictive accuracy across various populations.

01 Jul 2024·Phytomedicine

Betaine alleviates spermatogenic cells apoptosis of oligoasthenozoospermia rat model by up-regulating methyltransferases and affecting DNA methylation

Article

Author: Ge, Xiyu ; Han, Bangxing ; Liu, Dong ; Chen, Cunwu ; Wang, Huijun ; Su, Ting ; Gao, Leilei ; Ma, Menghua ; Chen, Yanjun ; Lin, Qiyan

BACKGROUNDOligoasthenozoospermia is the most common type of semen abnormality in male infertile patients. Betaine (BET) has been proved to have pharmacological effects on improving semen quality. BET also belongs to endogenous physiological active substances in the testis. However, the physiological function of BET in rat testis and its pharmacological mechanism against oligoasthenozoospermia remain unclear.PURPOSEThis research aims to prove the therapeutic effect and potential mechanism of BET on oligoasthenozoospermia rat model induced by Tripterygium wilfordii glycosides (TWGs).METHODSThe oligoasthenozoospermia rat model was established by a continuous gavage of TWGs (60 mg/kg) for 28 days. Negative control group, oligoasthenozoospermia group, positive drug group (levocarnitine, 300 mg/kg), and 200 mg/kg, 400 mg/kg, and 800 mg/kg BET groups were created for exploring the therapeutic effect of BET on the oligoasthenozoospermia rat model. The therapeutic effect was evaluated by HE and TUNEL staining. Immunofluorescence assay of DNMT3A, PIWIL1, PRMT5, SETDB1, BHMT2, and METTL3, methylation capture sequencing, Pi-RNA sequencing, and molecular docking were used to elucidate potential pharmacological mechanisms.RESULTSIt is proved that BET can significantly restore testicular pathological damage induced by TWGs, which also can significantly reverse the apoptosis of spermatogenic cells. The spermatogenic cell protein expression levels of DNMT3A, PIWIL1, PRMT5, SETDB1, BHMT2, and METTL3 significantly decreased in oligoasthenozoospermia group. 400 mg/kg and 800 mg/kg BET groups can significantly increase expression level of the above-mentioned proteins. Methylation capture sequencing showed that BET can significantly increase the 5mC methylation level of Spata, Spag, and Specc spermatogenesis-related genes. Pi-RNA sequencing proved that the above-mentioned genes produce a large number of Pi-RNA under BET intervention. Pi-RNA can form complexes with PIWI proteins to participate in DNA methylation of target genes. Molecular docking indicated that BET may not directly act as substrate for methyltransferase and instead participates in DNA methylation by promoting the methionine cycle and increasing S-adenosylmethionine synthesis.CONCLUSIONBET has a significant therapeutic effect on oligoasthenozoospermia rat model induced by TWPs. The mechanism mainly involves that BET can increase the methylation level of Spata, Specc, and Spag target genes through the PIWI/Pi-RNA pathway and up-regulation of methyltransferases (including DNA methyltransferases and histone methyltransferases).

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Oligoasthenozoospermia

Basic Info

Related

Analysis